Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06641180 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age
A Phase 3 study of Influenza, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,180
- Enrollment target
- 20
- Study locations
NCT06641180 is a Phase 3 study of Influenza that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 1,180 participants, below the 36,796-participant average among 156 other Influenza trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06641180, a Phase 3 study of Influenza, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,180 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate Immunogenicity and Safety of a High-Dose (HD) Influenza Vaccine (IV) in Adults 50 through 64 Years of Age.
Conditions Studied
Interventions
- BIOLOGICAL High-Dose trivalent influenza vaccine (Split virion, Inactivated)
- BIOLOGICAL Standard-dose trivalent influenza vaccine (Split virion, Inactivated)
Study Locations (20)
Georgia
- IACT Health - Columbus - Talbotton Road- Site Number : 8400011 - Columbus
- Cenexel IRA - iResearch Atlanta- Site Number : 8400007 - Decatur
- The Hope Clinic of Emory Vaccine Center- Site Number : 8400017 - Decatur
- Centricity Research - Rincon- Site Number : 8400012 - Rincon
- Cenexel IRS - iResearch Savannah- Site Number : 8400008 - Savannah
Florida
- Alliance for Multispeciality Research - Fort Myers- Site Number : 8400019 - Fort Myers
- Research Centers of America - Hollywood- Site Number : 8400010 - Hollywood
North Carolina
- Centricity Morehead- Site Number : 8400014 - Morehead City
- Centricity New Bern- Site Number : 8400015 - New Bern
California
- CenExel CNS- Site Number : 8400005 - Los Alamitos
Kansas
- Alliance for Multispeciality Research - Newton- Site Number : 8400003 - Newton
Kentucky
- Alliance for Multispeciality Research - Lexington- Site Number : 8400002 - Lexington
Maryland
- CBH Health - Gaithersburg- Site Number : 8400004 - Gaithersburg
New Jersey
- Hassman Research Institute - Berlin- Site Number : 8400006 - Berlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,180 participants |
| Start Date | 2024-11-04 |
| Est. Completion | 2025-06-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06641180
The ClinicalTrials.gov registry entry for NCT06641180 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,796-participant average among 156 other Influenza trials with a reported enrollment target (97% lower). The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which High-Dose trivalent influenza vaccine (Split virion, Inactivated) is the first listed.
NCT06641180 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Georgia, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06641180 about?
NCT06641180 is a clinical study titled "Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age". The purpose of this study is to evaluate Immunogenicity and Safety of a High-Dose (HD) Influenza Vaccine (IV) in Adults 50 through 64 Years of Age.
What is the current status of trial NCT06641180?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,180 participants. The study started on 2024-11-04. Estimated completion is 2025-06-24.
What conditions does trial NCT06641180 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT06641180?
The interventions under investigation include: High-Dose trivalent influenza vaccine (Split virion, Inactivated) (BIOLOGICAL), Standard-dose trivalent influenza vaccine (Split virion, Inactivated) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06641180?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06641180 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
RECRUITING · Phase 3
-
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
ACTIVE NOT RECRUITING · Phase 3
-
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years
COMPLETED · Phase 3
-
Study of Quadrivalent Influenza Vaccine Among Children
COMPLETED · Phase 3
-
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
COMPLETED · Phase 3
-
Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.